Sophiris Bio Long Term Debt

Sophiris Bio posts a long-term debt of $3.1M as of September 2019. That compares with $5.8M in the prior-year period — down 46.3% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Sophiris Bio's long-term debt was $5.8M. The latest reading is $3.1M — a 46.3% year-over-year decrease (period ending September 2019). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of Sophiris Bio's financial statement story. At $3.1M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for SPHS's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Sophiris Bio's other metric pages and overview cover the third.

Judging Sophiris Bio against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in long-term debt easier to interpret. Start with $3.1M here, then scan peer and history charts to see if the gap is persistent.